• 1
    Dandy FW, Margesson LJ. Hidradenitis suppurativa. Dermatol Clin2010; 28:1524.
  • 2
    Revuz J. Hidradenitis suppurativa. Presse Med2010; 39:125464.
  • 3
    Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol1996; 39:9714.
  • 4
    Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol2010; 90:2648.
  • 5
    Von der Werth JM, Jemec GBE. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol2001; 144:80913.
  • 6
    Nazary M, van der Zee HH, Prens EP et al. Pathogenesis and pharmacotherapy of hidradenitis suppurativa. Eur J Pharmacol2011; 672:18.
  • 7
    Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol2007; 156:516.
  • 8
    Van der Zee HH, van de Woude CJ, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br J Dermatol2010; 162:1957.
  • 9
    Van der Zee HH, de Ruiter L, van den Broecke DG et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol2010; 164:12928.
  • 10
    Giamarellos-Bournoulis EJ, Pelekanou A, Antonopoulou A et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol2008; 158:56772.
  • 11
    Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol2008; 158:3704.
  • 12
    Lee RA, Dommasch E, Treat J et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol2009; 60:56573.
  • 13
    Grant A, Gonzales T, Montgomery MO et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol2010; 62:20517.
  • 14
    Medzitov R. Toll-like receptors and innate immunity. Nat Rev Immunol2001; 1:13545.
  • 15
    Arbour NC, Lorenz E, Schutte BC et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet2000; 25:18791.
  • 16
    Uglialoro AM, Turbay D, Pesavento PA et al. Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens1998; 52:35967.
  • 17
    Smirnova I, Hamblin MT, McBride C et al. Excess of rare amino acid polymorphisms in the Toll-like receptor 4 in humans. Genetics2001; 158:165764.
  • 18
    Ferwerda B, McCall MBB, Alonso S et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci USA2007; 104:1664550.
  • 19
    Antonopoulou A, Baziaka F, Tsaganos T et al. Role of tumor necrosis factor gene single nucleotide polymorphisms in the natural course of 2009 influenza A H1N1 virus infection. Int J Infect Dis2012; 16:e204308.
  • 20
    O’Keefe GE, Hybki DL, Munford RS. The GA single nucleotide polymorphism at the -308 position in the tumor necrosis factor-alpha promoter increases the risk for severe sepsis after trauma. J Trauma2002; 52:81725.
  • 21
    Barber RC, Aragaki CC, Rivera-Chavez FA et al. TLR4 and TNF-alpha polymorphisms are associated with an increased risk for severe sepsis following burn injury. J Med Genet2004; 41:80813.
  • 22
    Slade DE, Powell BW, Mortimer PS. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg2003; 56:45161.
  • 23
    Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol2003; 149:21113.
  • 24
    Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered2008; 66:8798.
  • 25
    Nedoszytko B, Szczerkowska-Dobosz A, Zabłotna M et al. Associations of promoter region polymorphisms in the tumour necrosis factor-alpha gene and early-onset psoriasis vulgaris in a northern Polish population. Br J Dermatol2007; 157:1657.
  • 26
    Magalhães RF, Biral AC, Pancoto JA et al. Human leukocyte antigen (HLA) and single nucleotide polymorphisms (SNPs) tumor necrosis factor (TNF)-alpha -238 and -308 as genetic markers of susceptibility to psoriasis and severity of the disease in a long-term follow-up Brazilian study. Int J Dermatol2010; 49:113340.
  • 27
    Baran W, Szepietowski JC, Mazur G, Baran E. A -308 promoter polymorphism of tumor necrosis factor alpha gene does not associate with the susceptibility to psoriasis vulgaris. No difference either between psoriasis type I and type II patients. Acta Dermatovenerol Alp Panonica Adriat2006; 15:11318.
  • 28
    Van Limbergen J, Wilson DC, Satsangi J. The genetics of Crohn’s disease. Annu Rev Genomics Hum Genet2009; 10:89116.
  • 29
    Browning BL, Huebner C, Petermann I et al. Has Toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol2007; 102:250412.
    Direct Link:
  • 30
    De Jager PL, Franchimont D, Waliszewska A et al. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun2007; 8:38797.
  • 31
    Hume GE, Fowler EV, Doecke J et al. Novel NOD2 haplotype strengthens the association between TLR4 Asp299gly and Crohn’s disease in an Australian population. Inflamm Bowel Dis2008; 14:58590.
  • 32
    Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol2006; 154:7269.
  • 33
    Miller I, Lynggaard CD, Lophaven S et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol2011; 165:3918.
  • 34
    Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol2010; 146:5014.
  • 35
    Amano M, Grant A, Kerdel FA. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol2010; 49:9505.
  • 36
    Fardet L, Dupuy A, Kerob D et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol2007; 56:6248.
  • 37
    Cuchacovich M, Soto L, Edwardes M et al. Tumour necrosis factor (TNF) alpha −308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol2006; 35:43540.
  • 38
    Mascheretti S, Hampe J, Kühbacher T et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn’s disease treated with infliximab. Pharmacogenomics J2002; 2:12736.
  • 39
    Vasilopoulos Y, Manolika M, Zafiriou E et al. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol Diagn Ther2012; 16:2934.
  • 40
    Van der Zee HH, Laman JD, de Ruiter L et al. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol2012; 166:298305.
  • 41
    Grech I, Giatrakou S, Damoraki G et al. Single nucleotide polymorphisms of toll-like receptor-4 protect against acne conglobata. J Eur Acad Dermatol Venereol2012; 26:153843.